RG7916, the new investigational drug can help increase the level of survival motor neuron (SMN) proteins, which are usually lacking in babies with spinal muscular atrophy. The findings of this study are going to be presented at American Academy of Neurology's 70th Annual Meeting.
Spinal muscular atrophy (SMA)
is an inherited disease that leads to loss of motor function. It is the leading genetic cause of death in infants and toddlers. The disease is caused by reduced levels of the survival motor neuron (SMN) protein. In SMA, the SMN1 gene is mutated or missing. The backup SMN2 gene allows production of some of the necessary protein.
‘Since the spinal muscular atrophy is the result of reduced levels of the survival motor neuron (SMN) protein. The new drug RG7916 can modulate the SMN2 gene splicing to increase SMN protein and thereby increase survival chances.’
The new drug, called RG7916, is a liquid solution given orally once a day. It is designed to modulate the SMN2 gene splicing to increase SMN protein
The study involved babies with type 1 spinal muscular atrophy
who have two copies of the SMN2 gene. On average, these babies survive for 10.5 months before they die or need permanent breathing support.
The first phase of the study involved 21 babies who were three to seven months old at the start of the study. They were given the drug every day for four weeks at different dose levels.
Study results showed an increase of the SMN protein in the blood, with greater increases for higher doses of the drug. For the highest dose, the levels were up to 6.5 times higher after four weeks of treatment compared to levels at the beginning of the study
At the time of the analysis, 19 babies were alive. The two fatal events reported were disease-related and not considered related to the investigational drug. The average study duration for the 19 babies was four months with a range of one month to 13.5 months.
None of the 19 babies lost the ability to swallow, needed a tracheostomy for breathing or needed permanent breathing support during the study. There were no safety problems that required any babies to be removed from the study.
"These results are exciting, as children with SMA type 2, which is less severe than type 1, have approximately twice as much SMN protein as those with type 1 so to see an increase of up to 6.5 times the amount of protein is very encouraging and supports the possibility to see improved function in these babies," said study author Giovanni Baranello, MD, PhD, at the Carlo Besta Neurological Institute in Milan, Italy. "This research is continuing, and much more needs to be done to determine whether this treatment will provide meaningful benefits for children with spinal muscular atrophy."
Baranello noted that the first phase of the study was designed to assess the safety of the treatment and to find the right dose for the babies; it was not designed to determine how effective the treatment was. This will be assessed in the second phase of the study, which has started and is currently recruiting participants.